Abstract
Chordoma is a rare malignant bone tumor that expresses the transcription factor T. We conducted an association study of 40 individuals with chordoma and 358 ancestry-matched controls, with replication in an independent cohort. Whole-exome and Sanger sequencing of T exons showed strong association of the common nonsynonymous SNP rs2305089 with chordoma risk (allelic odds ratio (OR) = 6.1, 95% confidence interval (CI) = 3.1–12.1; P = 4.4 × 10−9), a finding that is exceptional in cancers with a non-Mendelian mode of inheritance.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Molecular features and vulnerabilities of recurrent chordomas
Journal of Experimental & Clinical Cancer Research Open Access 30 July 2021
-
Whole genome sequencing of skull-base chordoma reveals genomic alterations associated with recurrence and chordoma-specific survival
Nature Communications Open Access 03 February 2021
-
Synergistic drug combinations and machine learning for drug repurposing in chordoma
Scientific Reports Open Access 31 July 2020
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout

Accession codes
References
McMaster, M.L. et al. Cancer Causes Control 12, 1–11 (2001).
Yang, X.R. et al. Nat. Genet. 41, 1176–1178 (2009).
Tirabosco, R. et al. Am. J. Surg. Pathol. 32, 572–580 (2008).
Stemple, D.L. Development 132, 2503–2512 (2005).
Presneau, N. et al. J. Pathol. 223, 327–335 (2011).
Le, L.P. et al. PLoS ONE 6, e18846 (2011).
Stephens, P.J. et al. Cell 144, 27–40 (2011).
Papapetrou, C. et al. FEBS Lett. 409, 201–206 (1997).
Nelson, A.C. et al. J. Pathol. published, online doi:10.1002/path.4082 (30 July 30 July 2012).
The ENCODE Project Consortium. PLoS Biol. 9, e1001046 (2011).
Tuch, B.B. et al. PLoS ONE 5, e9317 (2010).
Vujovic, S. et al. J. Pathol. 209, 157–165 (2006).
Easton, D.F. et al. Hum. Mol. Genet. 17, R109–R115 (2008).
Genin, E. et al. Mol. Psychiatry 16, 903–907 (2011).
Satagopan, J.M. et al. Cancer Epidemiol. Biomarkers Prev. 10, 467–473 (2001).
Acknowledgements
We are grateful to the study subjects for participating in the research and to the clinicians and support staff in the London Sarcoma Service involved in their care. We thank S. McLaren, C. Latimer, K. Raine and A. Butler at the The Wellcome Trust Sanger Institute for assistance with the exome sequencing. We are also grateful to L. Game (Head of Genomics Laboratory, MRC Clinical Sciences Centre) for assistance with aCGH scanning. We are particularly grateful to B. Liegl (Medical University of Graz) for providing us with the chordoma cell line, MUG-Chor1. The research was funded by the Skeletal Cancer Action Trust (SCAT), UK, The Pathological Society (N. Pillay), The Chordoma Foundation, The Rosetrees Foundation and the Wellcome Trust Sanger Institute (grant 98051). The research was part of the RNOH Musculoskeletal Research Programme and Biobank and the UCL Hospital (UCLH)/UCL Comprehensive Biomedical Research Programme and was supported by the UCL Experimental Cancer Centre.
Author information
Authors and Affiliations
Contributions
N. Pillay and A.M.F. conceived and initiated the project and planned the experiments. V.P. and D.K. performed exome sequencing analysis and SNP6.0 array analysis. N. Pillay, D.H., F.B., P.S.T., S.B.L., N. Presneau, K.S. and J.P. performed the experiments. R.T., M.F.A., A.M.F., L.-G.K., P.J.T., S.M. and S.R.C. selected and provided the samples. N. Pillay, A.M.F. and V.P. wrote the manuscript. All authors reviewed and contributed to the final manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary Text and Figures
Supplementary Figures 1–8, Supplementary Tables 1–4 and Supplementary Methods (PDF 1562 kb)
Rights and permissions
About this article
Cite this article
Pillay, N., Plagnol, V., Tarpey, P. et al. A common single-nucleotide variant in T is strongly associated with chordoma. Nat Genet 44, 1185–1187 (2012). https://doi.org/10.1038/ng.2419
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ng.2419
This article is cited by
-
Update of pediatric bone tumors—notochordal tumors, chondrogenic tumors, and vascular tumors of the bone
Skeletal Radiology (2023)
-
Molecular features and vulnerabilities of recurrent chordomas
Journal of Experimental & Clinical Cancer Research (2021)
-
Targeted Therapy for Chordoma: Key Molecular Signaling Pathways and the Role of Multimodal Therapy
Targeted Oncology (2021)
-
Whole genome sequencing of skull-base chordoma reveals genomic alterations associated with recurrence and chordoma-specific survival
Nature Communications (2021)
-
Synergistic drug combinations and machine learning for drug repurposing in chordoma
Scientific Reports (2020)